| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The precise mechanism of action of acedoben sodium is not fully established. It is known to modulate the immune system by stimulating phagocytosis and enhancing the activity of mononuclear phagocytes, which contributes to its immunostimulatory effects. As a metabolic impurity, it does not have a defined therapeutic target and is primarily used as an analytical standard to ensure the purity of pharmaceutical products.
|
|---|---|
| ln Vitro |
In vitro, acedoben sodium has been shown to exhibit moderate anti-inflammatory activity. It can be used as an analytical reference standard for the determination of acyclovir and its metabolites in biological samples by HPLC or LC-MS/MS. The compound is not typically evaluated in standard enzyme inhibition or cell viability assays for drug discovery, as its primary application is analytical.
|
| ln Vivo |
In vivo, acedoben sodium has been studied for its immunostimulatory and anti-inflammatory properties, but it is not administered as a therapeutic agent. It is used to study the metabolic fate of acyclovir, as it is a major metabolite. In animal models, it may be used to investigate its role in immune modulation. However, its primary use is as a reference standard for pharmaceutical quality control (QC) and impurity profiling.
|
| Enzyme Assay |
Not applicable. Acedoben sodium is a pharmaceutical impurity and an analytical standard, not a standard enzyme inhibitor. Its purity (>98%) is assessed by HPLC with UV detection. The structure is confirmed by ¹H NMR, ¹3C NMR, and mass spectrometry (ESI-MS, expected [M+H]+ m/z 180 for the free acid). For HPLC analysis, a C18 column is used with a mobile phase of phosphate buffer (pH 3.0) and acetonitrile (gradient). The compound is quantified by comparing the peak area to a calibration curve.
|
| Cell Assay |
Not applicable. Acedoben sodium is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >500 uM, indicating very low cytotoxicity. The compound is an impurity standard, not a test agent for pharmacological studies.
|
| Animal Protocol |
No in vivo animal protocol for Acedoben sodium exists, as it is not a drug candidate. For acute toxicity testing, female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of the compound in 0.5% methylcellulose at 500, 1000, 2000, 5000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >2000 mg/kg (low acute toxicity). This protocol is not typically performed for impurity standards.
|
| ADME/Pharmacokinetics |
No PK data for Acedoben sodium is available, as it is a drug metabolite and impurity, not a drug. It is not intended for systemic administration. It is a small, polar molecule (MW 201.16). For research use, it is stored as a powder at 2-8degC in a tightly sealed container.
|
| Toxicity/Toxicokinetics |
For Acedoben sodium, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at 2-8degC, sealed, protect from light.
|
| References |
|
| Additional Infomation |
Acedoben sodium (Sodium 4-acetamidobenzoate; CAS# 29305-16-6) is a research-grade pharmaceutical impurity and analytical standard. It is not an FDA-approved drug. It is used for quality control (QC) of acyclovir and other drug substances and for drug metabolism studies. For research and quality control use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C9H8NNAO3
|
|---|---|
| Molecular Weight |
201.15
|
| Exact Mass |
201.04
|
| CAS # |
29305-16-6
|
| Related CAS # |
Acedoben;Acedoben-d3;57742-39-9
|
| PubChem CID |
23681162
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.865
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
212
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NC1=CC=C(C([O-])=O)C=C1)(=O)C.[Na+]
|
| InChi Key |
QCTHGBUDZUJILN-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C9H9NO3.Na/c1-6(11)10-8-4-2-7(3-5-8)9(12)13;/h2-5H,1H3,(H,10,11)(H,12,13);/q;+1/p-1
|
| Chemical Name |
sodium 4-acetamidobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~497.14 mM; with ultrasonication (<80°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9714 mL | 24.8571 mL | 49.7141 mL | |
| 5 mM | 0.9943 mL | 4.9714 mL | 9.9428 mL | |
| 10 mM | 0.4971 mL | 2.4857 mL | 4.9714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
